January 17, 2020 Posted By Categories Gary Schwitzer is the founder and publisher of HealthNewsReview.org. He is struggling to be an informed Medicare enrollee. He tweets as @garyschwitzer or @HealthNewsRevu. Since I’ve started writing more about Medicare now that I am more learned and experienced with the program as a person of that age group,… Read More »
Health Tech Nov 29, 2019• Today on THCB Spotlights, Matthew interviews Todd Clardy who is the EVP of Marketing at Accolade. Accolade is a company well-known for being in employee/patient advocacy. They’ve created an advocacy model that focuses on creating an outstanding member experience and supporting patients through their whole journey, whether it’s an acute… Read More »
November 5, 2019 Posted By Categories Gary Schwitzer is founder & publisher of HealthNewsReview.org. He has written many times about breast cancer screening and treatment controversies. He once produced breast cancer decision-making videos for the Foundation for Informed Medical Decision Making, which was the first funder of HealthNewsReview.org from 2005-2013. Breast Cancer Awareness Month is… Read More »
June 26, 2019 Posted By Categories Gary Schwitzer is the founder and publisher of HealthNewsReview.org. He tweets as @garyschwitzer or at @HealthNewsRevu. As a kid, I remember the song, “June is bustin’ out all over” from the musical Carousel. These days, June is Men’s Health Month, and with it comes some helpful reminders. But Twitter… Read More »
The Latest on lawsuits filed against opioid maker Purdue Pharma. 5:45 p.m. Hawaii has joined other states in filing lawsuits against opioid manufacturer Purdue Pharma. Hawaii Attorney General Clare Connors said in a statement Monday that she has filed lawsuits for violations of Hawaii’s Unfair and Deceptive Acts and Practices Law. One complaint alleges Purdue… Read More »
Sage Therapeutics has the first-ever approval for a prescription drug for postpartum depression, thanks to the FDA’s Tuesday nod for Zulresso. But it also has a number of big challenges ahead. Regulators greenlighted the product—a one-time injection—after a three-month delay, which they took to give themselves some extra time to work on a risk evaluation… Read More »